GSK PLC said Thursday that a Phase 3 trial of its respiratory syncytial virus vaccine candidate for adults aged over 60 years met its primary endpoint.
The U.K.-based maker of cancer and asthma medications
said that the vaccine candidate study showed a 94.1% reduction in severe RSV disease, and overall vaccine efficacy of 82.6%, meeting the trial’s primary endpoint. The vaccine was also well tolerated with a favorable safety profile, it added.
GSK said that regulatory submissions based on the results are anticipated in the second half of 2022.
“These are truly exceptional results given that today RSV remains one of the major infectious diseases without a vaccine, despite over 60 years of research,” Chief Scientific Officer Tony Wood said.
Write to Michael Susin at [email protected]